符合自体干细胞移植入组标准的弥漫性系统性硬化症患者接受常规治疗的结果
在澳大利亚硬皮病队列研究的492例弥漫性皮肤型系统性硬化症患者中,56例符合ASTIS试验入组标准、30例符合SCOT试验入组标准但未接受自体干细胞移植。这些患者4年无事件生存率分别为83.3%和81.2%,与ASTIS和SCOT试验中接受移植的患者相似,且优于接受环磷酰胺者。
要点
- 492例dcSSc中56例(11.4%)符合ASTIS入组标准,30例(6.1%)符合SCOT入组标准。
- 符合ASTIS和SCOT入组标准者4年无事件生存率分别为83.3%和81.2%。
- 同时符合入组与排除标准者4年无事件生存率分别为46.7%和45.7%。
核心结论
- 符合ASTIS和/或SCOT入组标准但未接受自体干细胞移植的ASCS患者,其4年无事件生存率与接受移植的患者相似,且优于ASTIS和SCOT试验中接受环磷酰胺的患者。
- 作者认为这可能反映无法控制的混杂因素(包括幸存者偏倚),也可能反映dcSSc标准治疗随时间的改善。
研究设计与样本
- 从多中心澳大利亚硬皮病队列研究(ASCS)中识别符合ASTIS和SCOT试验入组标准的患者。
- 评估4年无事件生存率(无心脏、肾脏或肺衰竭或死亡的生存),已接受移植的ASCS患者被排除分析。
主要发现
- ASCS中492例dcSSc患者,56例(56/492,11.4%)符合ASTIS入组标准,30例(30/492,6.1%)符合SCOT入组标准。
- 另有11例符合ASTIS或SCOT入组标准但因严重器官表现被排除。
- 符合ASTIS入组标准者4年无事件生存率为83.3%,符合SCOT入组标准者为81.2%。
- 同时符合ASTIS和SCOT入组标准但也符合排除标准者4年无事件生存率分别为46.7%和45.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出可能存在无法控制的混杂因素,包括幸存者偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to determine the event-free survival (EFS) of Australian patients with diffuse cutaneous systemic sclerosis (dcSSc) who met eligibility criteria for autologous stem cell transplant (ASCT) in previously published randomized controlled trials but were not treated with ASCT. METHODS: Patients who met inclusion criteria for the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) and Scleroderma: Cyclophosphamide Or Transplantation (SCOT) trials were identified from the multicenter Australian Scleroderma Cohort Study (ASCS). EFS (survival without cardiac, renal, or pulmonary failure or death) at 4 years was assessed. ASCS patients who had already undergone transplantation were excluded from analysis. RESULTS: Of the 492 patients with dcSSc in the ASCS, 56 met ASTIS inclusion criteria for ASCT (56 of 492 [11.4%]) and 30 met SCOT inclusion criteria (30 of 492 [6.1%]). An additional 11 patients met ASTIS or SCOT inclusion criteria, but they were excluded due to severe organ manifestations. EFS at 4 years in ASCS patients meeting ASTIS inclusion criteria was 83.3% and in ASCS patients meeting SCOT inclusion criteria was 81.2%. EFS at 4 years in ASCS patients who met ASTIS and SCOT inclusion but also exclusion criteria was 46.7% and 45.7%, respectively. CONCLUSION: ASCS patients meeting ASTIS and/or SCOT inclusion criteria who were not treated with ASCT have similar EFS at 4 years as patients receiving ASCT and better EFS than those receiving cyclophosphamide in the ASTIS and SCOT trials. This may reflect confounders unable to be controlled for, including survivor bias, but may also reflect improved standard of care for dcSSc over time.
引用
- Gregory K, Hansen D, Penglase R, et al. Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy. Arthritis Rheumatol. 2024. PMID: 38560777. doi:10.1002/art.42850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。